Esketamine

01/01/2021 - "Combination of Electroconvulsive Therapy Alternating With Intravenous Esketamine Can Lead to Rapid Remission of Treatment Resistant Depression."
10/01/2020 - "Esketamine is unlikely to be cost-effective for management of treatment-resistant depression in the United States unless its price falls by more than 40%."
01/01/2023 - "Intranasal esketamine effectively treats treatment-resistant depression in adults regardless of baseline irritability."
06/01/2022 - "Intranasal esketamine was demonstrated to be safe, well tolerated, and rapidly effective in individuals with treatment resistant depression, suicidal ideation, and suicidal behavior."
01/01/2019 - "Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established. "

03/01/1998 - "In rats, intrathecal S(+)-ketamine was effective for treating inflammatory pain. "
03/29/2023 - "While achieving pain relief in CRPS is challenging, esketamine infusions can accomplish pain relief for several weeks post-infusion in a subgroup of CRPS patients. "
08/19/2023 - "In this study, we aim to investigate the effect of esketamine on postoperative depression and pain in patients undergoing PD. "
03/29/2023 - "In addition, several secondary study parameters will be assessed in order to investigate mechanisms responsible for pain relief by esketamine infusions. "
03/29/2023 - "In this study, we investigate whether 6 intermittent outpatient esketamine treatments are not inferior to a continuous 6-day inpatient esketamine treatment in establishing pain relief. "

09/01/2021 - "Esketamine plus comprehensive standard of care rapidly reduces depressive symptoms in patients with major depressive disorder who have acute suicidal ideation or behavior, especially in those with a history of suicide attempt, providing a new treatment option for this particularly ill and vulnerable population."
11/01/2023 - "Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality."
12/12/2022 - "Rapidity of Symptom Improvement With Intranasal Esketamine for Major Depressive Disorder: A Systematic Review and Meta-Analysis."
08/01/2022 - "[The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature]."
01/01/2020 - "The authors sought to determine the efficacy of adjunctive intranasal esketamine in major depressive disorder (MDD). "

01/01/2023 - "S-ketamine is effective in reducing the early postoperative pain of patients who received abdominal surgery, and may not increase the incidence of postoperative complications."
01/01/2016 - "Efficacy of Continuous S(+)-Ketamine Infusion for Postoperative Pain Control: A Randomized Placebo-Controlled Trial."
01/01/2023 - "To evaluate the efficacy of a single preoperative dose of S-ketamine for chronic postsurgical pain (CPSP) in patients undergoing video-assisted thoracoscopic surgical lung lesion resection (VATS). "
11/25/2023 - "In this study, esketamine can prevent early postoperative pain effectively. "
09/01/2023 - "Trial Sequence Analysis for Assessing the Impact of S-Ketamine on Postoperative Pain."

09/01/2023 - "Exploring the potential of Esketamine in the treatment of bipolar depression."
07/01/2021 - "Intranasal esketamine use in bipolar disorder: A case report."
01/01/2021 - "70 patients with unipolar or bipolar depression were treated with 6 weekly subcutaneous esketamine infusions (0.5-1mg/kg). "
01/01/2017 - "Rapid infusion of esketamine for unipolar and bipolar depression: a retrospective chart review."
10/01/2022 - "Efficacy of esketamine did not differ between groups (major depressive disorder vs bipolar depression) at any timepoint. "